Bioactivx and UltiMaker: 3D Printing in Regulated Skin-Substitute Manufacturing
The Singapore project shows how FFF can become part of a regulated manufacturing workflow for medical end products.
What is being made?
Bioactiv Matrix is a synthetic skin substitute; the company uses proprietary filament and a controlled printing process.
Regulatory context
The report cites Singapore HSA approval and operations under ISO 13485. This does not imply automatic approval in other jurisdictions.
Why it matters
Additive manufacturing is part of a documented and controlled production process rather than a demonstration prototype.














